Since 2014
Venous thrombo-embolism (VTE) prevention of patients undergoing total hip and knee replacement: budget impact analysis of apixaban in Italy
Farmeconomia
View Archive Info| Field | Value | |
| Title |
Venous thrombo-embolism (VTE) prevention of patients undergoing total hip and knee replacement: budget impact analysis of apixaban in Italy
|
|
| Creator |
Mantovani, Lorenzo Giovanni
Di Minno, Giovanni Furneri, Gianluca |
|
| Subject |
—
Apixaban, New oral anticoagulants, Venous thromboembolism |
|
| Description |
BACKGROUND: Venous thromboembolism (VTE) is a common and burdensome cardiovascular condition, frequently leading to severe complications and requiring high-cost healthcare interventions. New oral anticoagulants (nOACs) have demonstrated to be efficacious and safe in VTE prevention of patients undergoing total hip replacement (THR) and total knee replacement (TKR), a condition that is typically associated to cardiovascular disease. The Italian Healthcare Service (SSN) has recently approved the latest nOAC, apixaban. The present article aims to evaluate its economic impact in the perspective of the Italian SSN.METHODS: We conducted a budget impact analysis to estimate clinical outcomes and economic consequences associated to the reimbursement of apixaban, in the prevention of VTE as a consequence of major orthopedic surgery, over a three-year time horizon. In our analysis we compared two alternative scenarios, with apixaban either reimbursed (Scenario B) or not reimbursed (Scenario A) by the Italian SSN, and estimated the difference of healthcare costs between the two scenarios. Only direct healthcare costs have been considered.RESULTS: According to market assumptions, it is estimated that 1.2%, 3.7%, and 6.5% of THR patients, and 1.2%, 3.8% and 6.7% of TKR patients, would be treated with apixaban over the first three years since launch. At the estimated daily cost of apixaban (€2.48/die), this would translate into a budget impact of €14.3 mln, €45.5 mln, and €81.4 mln at years 1, 2 and 3 since launch, respectively. This expenditure would be more than offset by savings, due to: i) reduction of prescriptions of alternative treatment options (other nOACs, low-molecular weight heparins, fondaparinux); ii) reduction of the economic burden attributable of CV complications of VTE. Finally, Scenario B resulted slightly favourable compared to Scenario A, leading to economic savings for about €50 thousands over three years. Sensitivity analyses confirmed findings of the base-case analysis.CONCLUSIONS: Reimbursement of apixaban does not determine a budget impact increase for Italian SSN. Its usage may be considered fully sustainable from a pharmaco-economic viewpoint.
|
|
| Publisher |
SEEd Medical Publishers
|
|
| Contributor |
Study funded by Bristol-Myers Squibb and Pfizer
|
|
| Date |
2013-09-11
|
|
| Type |
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion — |
|
| Format |
text/html
application/pdf |
|
| Identifier |
https://journals.seedmedicalpublishers.com/index.php/FE/article/view/670
10.7175/fe.v14i3.670 |
|
| Source |
Farmeconomia. Health economics and therapeutic pathways; Vol 14, No 3 (2013); 119-129
2240-256X |
|
| Language |
eng
|
|
| Relation |
https://journals.seedmedicalpublishers.com/index.php/FE/article/view/670/1001
https://journals.seedmedicalpublishers.com/index.php/FE/article/view/670/1002 |
|
| Coverage |
—
— — |
|
| Rights |
Copyright (c) 2013 Farmeconomia. Health economics and therapeutic pathways
http://creativecommons.org/licenses/by-nc/4.0 |
|